ClearPoint Neuro stock holds recent gains as earnings and analyst targets frame the next move
Published on 08/29/2026 at 13:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
ClearPoint Neuro, Inc. (ISIN US18507C1099) has seen its stock price move into the mid-teens in 2026, with the latest available close of $15.94 on August 27, 2026 setting the stage for investors assessing its path after recent earnings and updated analyst views.
Recent earnings and revenue trends
Per a recent overview of ClearPoint Neuro's financials, the company reported a quarterly loss of $0.38 per share for its latest published quarter, versus a consensus expectation of a $0.29 loss, highlighting a gap of $0.09 per share that underscored continued investment and operating costs in the period as of the August 3, 2026 report. The same quarterly release showed revenue of $10.88 million against analyst estimates of $12.73 million, indicating that reported sales fell $1.85 million short of the consensus figure for that quarter. In addition to these point-in-time figures, ClearPoint Neuro's trailing twelve-month metrics for the period referenced in the August 3, 2026 data include a negative return on equity of 188.09 percent and a negative net margin of 81.76 percent, underlining that the company remains in a growth and investment phase rather than a mature profit-generating state.
Those numbers give a clearer sense of where ClearPoint Neuro stands in its most recent reporting window, with the earnings miss versus expectations and revenue shortfall suggesting that execution and cost control were key discussion points during and after the August 3, 2026 quarterly release. For investors, the combination of double-digit million revenue, substantial negative margins, and a loss per share notably wider than consensus indicates that the company is still working toward scaling its neurosurgical platform in a way that can support more sustainable profitability over the next several quarters.
Stock performance and valuation context
From a market perspective, ClearPoint Neuro's share price has strengthened across 2026. Data compiled in late August 2026 shows that the stock was trading at $13.68 on January 1, 2026 and has since moved up to $15.94 as of the close on August 27, 2026, a gain of 16.5 percent year to date. An intraday snapshot connected to the same data set also notes that shares recently opened at $15.55 in the latest session cited, placing the stock modestly below the prior close and indicating some short-term volatility around the mid-teens price zone even after the broader year-to-date advance.
Alongside that price action, ClearPoint Neuro's market capitalization was recently reported at $474.34 million in the same late August 2026 market data, giving investors a sense of the valuation the market currently assigns to its neurosurgical navigation and therapy platform. When the $15.94 share price as of August 27, 2026 is viewed against the consensus price target of $25.67 cited in recent analyst coverage, the implied upside to that target is nearly $9.73 per share or more than 60 percent, suggesting that covering analysts see meaningful potential if the company can deliver on its growth and profitability objectives.
Analyst views and ratings backdrop
Recent coverage summarizing ClearPoint Neuro's stock indicates that two analysts currently rate the shares as a Buy while one rates them as a Sell, leading to an overall average rating characterized as Hold. This mixed stance reflects both confidence in the long-term opportunity of the company's neurosurgical technology and caution stemming from the negative margins and earnings misses that still define the latest reported quarter as of August 3, 2026. The consensus price target of $25.67 set by these analysts, taken together with the current trading level near $15.94, reinforces that the Street sees room for appreciation but is not uniformly bullish.
Calendar data from the same late August 2026 overview lists the last earnings date as August 3, 2026 and places an estimated next earnings date on November 5, 2026, with the fiscal year ending December 31, 2026. While the November 5, 2026 figure is framed as an estimate rather than a formally announced date, it helps investors anticipate when the next update on ClearPoint Neuro's revenue trajectory, margins, and per-share results might arrive, which in turn could drive reassessment of both ratings and price targets depending on whether the company narrows its losses and improves its operating metrics.
Business model and neurosurgical platform
ClearPoint Neuro focuses on providing MRI-guided navigation and therapy platforms designed to support precise interventions in the brain and central nervous system. The company works with neurosurgeons and hospitals to integrate its technology into operating rooms, enabling more accurate placement of instruments and delivery of therapies during procedures that range from biopsies to deep brain stimulation and drug delivery. This positioning in the medical devices and neurosurgical space means that its revenue growth is tied to system placements, procedure volumes, and adoption by leading centers that value imaging-guided precision.
The negative margin profile evident in its latest quarterly results as of August 3, 2026 is consistent with a company investing in research and development, clinical collaborations, and commercialization efforts to expand the installed base of its platform. For investors, the key question over the coming quarters will be whether ClearPoint Neuro can convert its clinical and technological advantages into higher recurring revenue from disposables and services, and over time scale the business so that fixed costs are spread across a larger revenue base, thereby improving the net margin from the currently negative 81.76 percent to a more sustainable level.
Representative product: MRI-guided neurosurgical system
A representative product in ClearPoint Neuro's portfolio is its MRI-compatible neurosurgical navigation system, which is designed to allow surgeons to perform minimally invasive procedures in the brain with real-time imaging feedback. This system integrates specialized hardware that can be safely used within an MRI environment with software that helps plan and execute the trajectory of instruments, enhancing accuracy and reducing the risk of damage to surrounding tissue. By focusing on this kind of platform, ClearPoint Neuro aims to support more effective treatments for conditions such as movement disorders, brain tumors, and other neurological diseases, while giving hospitals a differentiated tool that fits into their existing imaging infrastructure.
Price level and investor angle
As of the latest completed regular session on August 27, 2026, ClearPoint Neuro stock closed at $15.94 on its Nasdaq listing, with an intraday indication of shares opening at $15.55 in the most recent trading reference. This places the stock at a valuation of roughly $474.34 million, and with year-to-date performance up 16.5 percent from the $13.68 level at the start of 2026, the shares have delivered a mid-teens percentage gain for investors this year while still trading below the $25.67 consensus target cited in current analyst coverage.
Read more
Further details on ClearPoint Neuro's latest earnings, revenue figures, analyst ratings, and calendar, including the August 3, 2026 quarterly data and the current consensus target, can be found in a comprehensive late August 2026 stock overview that aggregates these metrics for investors tracking CLPT.
Fact box
Company: ClearPoint Neuro, Inc.
ISIN: US18507C1099
Ticker: CLPT
Exchange: Nasdaq
Price (as of August 27, 2026, 4:00 p.m. ET): $15.94 USD
Market cap: $474.34 million (as of August 28, 2026)
Sector / Industry: Medical Devices
Index membership: Nasdaq composite
